Dr. John Catanzaro serves as CEO, Founder, Chairman, and Product Development Officer of Neo7Bioscience, a precision/personalized molecular design biotech company. Dr. Catanzaro received his Doctorate of Naturopathic Medicine (NMD) from Bastyr University in 1995 and his Doctorate of Theology in Science and Medical Ethics (Ph.D. and Th.D.) from Bethany Divinity Seminary in 2012. After 22 years of clinical practice treating patients with cancer and chronic illness, he retired in 2017, where he was the founder and CEO of a cancer institute and research development group of genetic and proteomic technology innovating patient-precision genetically matched immunopeptides. In addition, Dr. Catanzaro is the co-inventor of a precision augmentation platform known as PBIMA. The platform includes multiomic/proteomic sequencing and prediction, CRISPR prime editing features, and proteomics in a 3D integration utilizing unified proprietary mapping informatics and computation, superior ranking, and selection architecture. Dr. Catanzaro is a thought leader in molecular bioscience and biotechnology and brings forth a wealth of knowledge and experience to architect precision-based personalized therapeutics in healthcare. Before his career in medicine and biosciences, he was in various capacities in the aerospace industry, including stints for the USAF and The Boeing Company. Dr. Catanzaro is currently engaged in life science in space and astrobiological research. "My special interest and focus is molecular engineering in space, working with SpacePharma to develop autonomous minisatellite laboratories with diverse orbit and deep space exploration capabilities."